Tiziana Life Sciences (TLSA) Total Non-Current Liabilities (2019 - 2025)

Tiziana Life Sciences (TLSA) has reported Total Non-Current Liabilities for 7 consecutive years, with $7.4 million the latest figure, recorded in Q2 2025.

• Quarterly Total Non-Current Liabilities fell 18.82% year-over-year to $7.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $7.4 million (down 18.82% YoY) and the FY2024 annual result came in at $7.3 million, up 10.58% from the prior year.
• Total Non-Current Liabilities rose to $7.4 million in Q2 2025 per TLSA's latest filing, from $7.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for TLSA reached as high as $9.2 million in Q2 2021 and fell as low as $4.1 million in Q2 2023.
• A 5-year average of $7.0 million and a median of $7.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 42.68% — and 2024, when it jumped 121.06%.
• Year by year, Total Non-Current Liabilities stood at $7.5 million in 2021, then decreased by 13.2% to $6.5 million in 2022, then advanced by 1.42% to $6.6 million in 2023, then rose by 10.58% to $7.3 million in 2024, then climbed by 0.71% to $7.4 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.4 million, $7.3 million, and $9.1 million for Q2 2025, Q4 2024, and Q2 2024 respectively.